Hyundai Pharm Receives Domestic Approval for Phase 2 Clinical Trial of New Diabetes Treatment Drug

[Asia Economy Reporter Chunhee Lee] Hyundai Pharm announced on the 21st that it has received approval from the Ministry of Food and Drug Safety for the domestic Phase 2 clinical trial of the oral type 2 diabetes treatment new drug candidate ‘HDNO-1605 (HD-6277)’.

This Phase 2 clinical trial will be conducted to exploratively verify the efficacy and safety of HD-6277 in patients with type 2 diabetes.

HDNO-1605 (HD-6277) is a type 2 diabetes treatment candidate targeting the GPR40 receptor, which regulates insulin secretion in the body. It is explained to have a low risk of side effects such as hypoglycemia while demonstrating excellent blood sugar control with once-daily administration.

A Hyundai Pharm official stated, “The commencement of this Phase 2 clinical trial will be an important step closer to developing a new mechanism diabetes drug,” and added, “We expect that the new drug development will provide safe and effective options for medical professionals and patients.”